


CANCER GENOMICS & PROTEOMICS

Volume 21, Number 3, May-June 2024

ISSN (online): 1790-6245



Editorial Board

A. Seth	Editor-in-Chief Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
G.J. Delinasios	Managing Editor and Executive Publisher International Institute of Anticancer Research, Athens, Greece
L.A. Aaltonen	Department of Medical Genetics, University of Helsinki, Helsinki, Finland
R. Abagyan	The Scripps Research Institute, La Jolla, CA, USA
D.-T. Bau	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
R. Clarke	Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
A.M. Dubuc	Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
T. Efferth	Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany
N.A. Ellis	Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
A. Facchetti	Fondazione CNAO, Pavia, Italy
M.D. Filiou	Department of Biological Applications and Technology, University of Ioannina & Biomedical Research Institute, FORTH, Ioannina, Greece
C.V. Forst	Department of Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
G. Glinsky	Institute of Engineering in Medicine, University of California, San Diego, CA, USA
T.R. Golub	Pediatric Oncology, Dana-Farber Cancer Institute, Cambridge, MA, USA
J. Gordon	Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA, USA
C.-H. Heldin	Ludwig Institute for Cancer Research, Uppsala, Sweden
J.D. Hoheisel	Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
T.H.M. Huang	Department of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
S.C. Jhanwar	Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J. Ju	Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA
O.P. Kallioniemi	Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
K. Khalili	College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
D.G. Kieback	Helios Medical Center Schleswig, Schleswig, Germany
S.D. Kottaridis	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
Y. T. Kwon	Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea
B. Léylund-Jones	National Foundation for Cancer Research (NFCR), Rockville, MD, USA
P. Lichter	Deutsches Krebsforschungszentrum, Heidelberg, Germany
A. Lindblom	Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden
G. Lubec	Department of Pediatrics, University of Vienna, Austria
P.J. McCormick	The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
F. Mitelman	Department of Clinical Genetics, University Hospital, Lund, Sweden
C. Nicot	Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA
L. O'Driscoll	School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
C.D. Platsoucas	College of Sciences, Old Dominion University, Norfolk, VA, USA
J. Quackenbush	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
J.S. Rader	Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
R.H. Reeves	Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA

CANCER GENOMICS & PROTEOMICS

Online ISSN: 1790-6245

Editor-in-Chief:

ARUN SETH, *Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada*

Managing Editor:

G.J. DELINASIOS, *International Institute of Anticancer Research (IAR), Kapandriti, Attiki, Greece*

Managing Editor (2004-2016):

J.G. DELINASIOS, *International Institute of Anticancer Research (IAR), Kapandriti, Attiki, Greece*

Editorial Board

L.A. Aaltonen, *Helsinki, Finland*

R. Abagyan, *La Jolla, CA, USA*

D.-T. Bau, *Taichung, Taiwan, ROC*

R. Clarke, *Washington, DC, USA*

A. M. Dubuc, *Boston, MA, USA*

T. Efferth, *Mainz, Germany*

N.A. Ellis, *Tucson, AZ, USA*

A. Faccoetti, *Pavia, Italy*

M.D. Filiou, *Ioannina, Greece*

C.V. Forst, *New York, NY, USA*

G. Glinsky, *San Diego, CA, USA*

T.R. Golub, *Cambridge, MA, USA*

J. Gordon, *Philadelphia, PA, USA*

C.-H. Heldin, *Uppsala, Sweden*

J.D. Hoheisel, *Heidelberg, Germany*

T.H.M. Huang, *San Antonio, TX, USA*

S.C. Jhanwar, *New York, NY, USA*

J.Ju, *Stony Brook, NY, USA*

O.P. Kallioniemi, *Turku, Finland*

K. Khalili, *Philadelphia, PA, USA*

D.G. Kieback, *Schleswig, Germany*

S.D. Kottaridis, *Athens, Greece*

Y.T. Kwon, *Seoul, Republic of Korea*

B. Léylund-Jones, *Rockville, MD, USA*

P. Lichter, *Heidelberg, Germany*

A. Lindblom, *Stockholm, Sweden*

G. Lubec, *Vienna, Austria*

P.J. McCormick, *Rensselaer, NY, USA*

F. Mitelman, *Lund, Sweden*

C. Nicot, *Kansas City, KS, USA*

L. O'Driscoll, *Dublin, Ireland*

C. D. Platsoucas, *Norfolk, VA, USA*

J. Quackenbush, *Boston, MA, USA*

J.S. Rader, *Milwaukee, WI, USA*

R.H. Reeves, *Baltimore, MD, USA*

T. Ried, *Bethesda, MD, USA*

G. Rimbach, *Kiel, Germany*

K.D. Rodland, *Richland, WA, USA*

C. Sansom, *London, UK*

N.A. Saunders, *Queensland, Australia*

B.W. Schäfer, *Zurich, Switzerland*

J. Schneider, *Valladolid, Spain*

O.J. Semmes, *Norfolk, VA, USA*

G.V. Sherbet, *Newcastle-upon-Tyne, UK*

S. Smith, *Duarte, CA, USA*

J.C. Strefford, *Southampton, UK*

G. Tsangaris, *Athens, Greece*

U.H. Weidle, *Penzberg, Germany*

H. Zhang, *New Haven, CT, USA*

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd.,

P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

U.S. Branch: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: journals@iiar-anticancer.org (Editorial Office)

editor@iiar-anticancer.org (Managing Editor)

www.iiar-anticancer.org

http://cgp.iiarjournals.org

Front cover photograph: Figure 1, page 262.

Editorial Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The Journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-2 months from acceptance.

For more information about CANCER GENOMICS & PROTEOMICS, IAR and the Conferences, please visit the IAR website: www.iiar-anticancer.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly online-only and open access by the International Institute of Anticancer Research. Each annual volume comprises of six issues. CANCER GENOMICS & PROTEOMICS Vol. 1 (2004) and onwards appears online with Stanford University HighWire Press. All published articles are deposited in PubMed Central.

Open Access Policy: CGP appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of US\$ 950.00 (effective January 1, 2023) for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged US\$ 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. CGP online will keep the volume and issue numbers, as well as page numbering.

Copyright: Authors retain copyright. The unrestricted *non-commercial* use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and HTML files of all articles published in CGP are the property of the publisher.

Manuscripts and correspondence should be addressed to: Dr. George J. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, University of Toronto, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737. E-mail: genomics.proteomics@utoronto.ca

The Editors and Publishers of CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2024, International Institute of Anticancer Research (Dr. George J. Delinasios). All rights reserved

PHOTO COMPOSITION BY IAR

CANCER GENOMICS & PROTEOMICS

Print ISSN (2004-2012): 1109-6535
Online ISSN: 1790-6245

VOLUME 21, No 3
2024

T. Ried	Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
G. Rimbach	Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
K.D. Rodland	Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
C. Sansom	The School of Crystallography, Birbeck College, University of London, London, UK
N.A. Saunders	Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia
B.W. Schäfer	Department of Oncology, University Children's Hospital, Zurich, Switzerland
J. Schneider	Universidad de Valladolid, Valladolid, Spain
O.J. Semmes	Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
G.V. Sherbet	University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
S. Smith	City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
J.C. Strefford	Cancer Science Division, Southampton General Hospital, Southampton, UK
G. Tsangaris	Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
U.H. Weidle	Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
H. Zhang	Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PubMed, PubMed Central, MEDLINE, CAS (Chemical Abstracts Service); Biological Abstracts; EMBASE and BIOBASE; Compendex, GEOBASE; EMBiology; FLUIDEX; Scopus (Elsevier Bibliographic Databases); BIOSIS Previews; Science Citation Index Expanded (Web of Science); Essential Science Indicators; Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub; Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. Web: www.iiar-anticancer.org; www.cgp.iiarjournals.org.

Editorial Office in U.S.A.: Anticancer Research USA, Inc., 111 Bay Avenue, Highlights, NJ 07732, USA.

E-mail: journals@iiar-anticancer.org. Managing Editor: editor@iiar-anticancer.org.

Web: www.iiar-anticancer.org; www.cgp.iiarjournals.org.

Manuscripts and correspondence should be addressed to: Dr. George J. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: genomics.proteomics@utoronto.ca

CANCER GENOMICS & PROTEOMICS

Volume 21, Number 3, May-June 2024

Articles

- Deregulated circRNAs in Epithelial Ovarian Cancer With Activity in Preclinical *In Vivo* Models: Identification of Targets and New Modalities for Therapeutic Intervention. U.H. WEIDLE, F. BIRZELE (*Penzberg, Germany; Basel, Switzerland*) 213
- Genomic Frequencies of Dynamic DNA Sequences and Mammalian Lifespan. M. MARTELLA, N. CARLESSO, Z.A.E. WALLER, G. MARCUCCI, F. PICHIORRI, S.S. SMITH (*Duarte, CA, USA; London, UK*) 238
- Fusion of Platelet Derived Growth Factor Receptor Alpha (*PDGFRA*) With Ubiquitin Specific Peptidase 8 (*USP8*) in a Calcified Chondroid Mesenchymal Neoplasm Harboring t(4;15)(q12;q21) as a Sole Aberration. I. PANAGOPOULOS, K. ANDERSEN, L. GORUNOVA, I. LOBMAIER (*Oslo, Norway*) 252
- Genetic Analyses of Primary Liver Cancer Cell Lines: Correspondence With Morphological Features of Original Tumors. J. AKIBA, S. OGASAWARA, H. YANO (*Fukuoka, Japan*)..... 260
- Germline *MYOF1::WNK4* and *VPS25::MYOF1* Chimeras Generated by the Constitutional Translocation t(17;19)(q21;p13) in Two Siblings With Myelodysplastic Syndrome. I. PANAGOPOULOS, K. ANDERSEN, V. STAVSETH, S. TORKILDSEN, S. HEIM, M.R. TANDSÆTHER (*Oslo; Levanger, Norway*) 272
- Engineering of an EPHA2-Targeted Monobody for the Detection of Colorectal Cancer. A. VENU, Y. ZHANG, J. SEONG, Y. HONG, W.-S. LEE, J.-J. MIN (*Hwasun; Jeonnam; Gwangju, Republic of Korea*)..... 285
- Impact of Prospero Homeobox-1 (*PROX-1*) on the Oncogenic Phenotypes of Hepatocellular Carcinoma Cells. J.-Y. HONG, S.-Y. PARK, Y.-L. PARK, G.-R. YOU, J.H. YOON, Y.-E. JOO, S.K. CHOI, S.-B. CHO (*Gwangju, Republic of Korea*)..... 295
- The Important Role of GPX1 and NF- κ B Signaling Pathway in Human Gastric Cancer: Implications for Cell Proliferation and Invasion. B.I. JANG, J.Y. JUNG, S.A. KOH, K.H. LEE (*Daegu, Republic of Korea*)..... 305
- Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and Degree of Immune Cell Infiltration in Triple-negative Breast Cancer. K. SATO, K. MIURA, S. TAMORI, K. AKIMOTO (*Chiba, Japan*) 316